| Literature DB >> 34690522 |
Abstract
This paper reviews recent findings on the normative analysis of private and governmental countermeasures against infectious diseases, focusing on COVID-19. Based on a model that relates the economic activity to infectious disease epidemics, policies that maximize social welfare are considered. Lockdowns in many countries are measures that restrict economic activity over a wide area, and the economic damage they cause is extremely large. Existing studies on the net benefit of lockdown implemented in 2020 have reached mixed conclusions as to whether it is warranted or not. Although the estimates of costs and effects are relatively stable, the setting of the value of a statistical life for converting effects into benefits has a wide range and is also likely to overestimate benefits. Therefore, a careful procedure for setting is particularly crucial to obtain a reliable evaluation of countermeasures. Compared to uniform restriction of activities, taking measures to restrict activities by selecting targets may improve efficiency. Attributes that can be used to select targets include those that can be identified at little or no cost, such as age and industry, and those that can only be identified at a cost, such as close contact with infectious individuals and the presence of pathogens. In comparison to lockdown, these measures may reduce human suffering and economic suffering. No trade-off exists between uniform activity restrictions and selective activity restrictions.Entities:
Keywords: COVID-19; Cost–benefit analysis; Economic epidemiology; Externalities; Lockdown; SIR model; Value of a statistical life
Year: 2021 PMID: 34690522 PMCID: PMC8521080 DOI: 10.1007/s42973-021-00096-6
Source DB: PubMed Journal: Jpn Econ Rev (Oxf) ISSN: 1352-4739
The value of a statistical life
| Value of a living year | Average remaining life of dead | Value of a statistical life | |
|---|---|---|---|
| EPA | 6 years of consumption | 40 years | 240 years of consumption |
| Hall et al. | 3.5 years of consumption | 14.5 years | 51 years of consumption |
| Alvarez et al. | 3 years of consumption | 10 years | 30 years of consumption, or 20 years of GDP |
Consumption and GDP are per capita
Fig. 1Settings of reduction of transmission occasion and its costs. The horizontal axis is the reduction rate of transmission rate. The vertical axis is the reduction rate of output
Comparison of incremental cost–effectiveness ratio and value of a statistical life
| Cost per capita | Effect per 1000 persons | ICER | VSL | NSB (billion) | |
|---|---|---|---|---|---|
| (United States) | |||||
| Broughel and Kotrous | 2.85 | 338,000 | 301.0–550.8 | ||
| Doti | 1.08 | 1,145,000 | 4,200,000 | (N.A.) | |
| Scherbina | 653.1 | ||||
| Thunstrom et al. | 3.75 | 10,000,000 | 5160 | ||
| (United Kingdom) | |||||
| Miles et al. | 6.58 | 300,000 | − 547 to − 68 | ||
| Rowthorn and Maciejowski | 5.68 | 2,000,000 | (N.A.) |
The unit is US dollars and UK pounds. Italic indicates the value not reported in the reference, but complemented by the author. “Effect” indicates the lives saved by countermeasures against COVID-19
Fig. 2Incremental cost–effectiveness ratio and value of a statistical life. Unit of both axes is US dollar. The horizontal axis is ICER. The vertical axis is VSL. On the straight line, ICER and VSL are equal. On the upper left of the straight line, VSL is greater than ICER and B/C is greater than 1. At the bottom right of the line, ICER is greater than VSL and B/C is less than 1
Estimates of other parameters in ex post evaluations of lockdown
| Coverage of costs | Coverage of effects | Coverage is consistent | Costs per week | Costs | Costs are related with effects | Effects | Consideration of other effects | |
|---|---|---|---|---|---|---|---|---|
| (United States) | ||||||||
| Broughel and Kotrous | Stay-at-home orders | Total | No |
|
| No | 940,000–1,040,000 | Yes |
| Doti | Stay-at-home orders | Stay-at-home orders | Yes | 410b | Yes | 358,000 | No | |
| Scherbina | Stay-at-home orders | Total | No | 36.93b |
| No |
| Yes |
| Thunstrom et al. | Total | Total | Yes | 7.21t | No | 1,239,000 | No | |
| (United Kingdom) | ||||||||
| Miles et al. | Total | Total | Yes | (9–25% of GDP) | No | 20,000–440,000 | No | |
| Rowthorn and Maciejowski | Total | Total | Yes | 200 (per capital) | Yes | 380,000 | Yes |
This table presents the estimates of parameters that did not appear in Table 2. The unit of costs is US dollars and UK pounds. Italic indicates the value not reported in the reference, but complemented by the author. “Coverage is consistent”: when costs and effects are estimated, the study focuses on the same measures against COVID-19. “Costs are related with effects”: the study explicitly connects the effects of measures against COVID-19 with their costs. “Effects”: lives saved. “Consideration of other effects”: the effects include not only lives saved but also reduction of non-fatal loss.